Valbiotis successfully raises €10.2 million in capital

Valbiotis has announced the successful completion of its €10.2 million capital increase. This operation, dedicated to the commercial expansion of the company's natural health products, met with significant demand. Total subscriptions reached 7.2 million shares at a price of €0.86 per share, representing 60.85% of the maximum number planned.

This fundraising round, supported by shareholders, institutional investors, and Mr. Tao's company Ximen RD PTE Ltd, aims to accelerate Valbiotis's development in France and internationally. The funds will notably allow the company to strengthen its sales network and ensure a stable supply.

The net proceeds from the issuance, estimated at €8.9 million, will be primarily allocated to working capital and marketing development. The transaction has resulted in the planned listing of the new shares on Euronext Growth Paris on June 30, 2026.